Literature DB >> 22550350

Cholinesterase inhibitors and memantine for symptomatic treatment of dementia.

Joanne Rodda1, Janet Carter.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22550350     DOI: 10.1136/bmj.e2986

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  17 in total

1.  The "Rising Tide" of dementia in Canada: What does it mean for pharmacists and the people they care for?

Authors:  Feng Chang; Tejal Patel; Mary E Schulz
Journal:  Can Pharm J (Ott)       Date:  2015-07

2.  Research priorities in geriatric palliative care: nonpain symptoms.

Authors:  Sara Combs; Benzi M Kluger; Jean S Kutner
Journal:  J Palliat Med       Date:  2013-07-26       Impact factor: 2.947

Review 3.  Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Philip L De Jager
Journal:  Biochem Pharmacol       Date:  2014-02-06       Impact factor: 5.858

Review 4.  Improving the predictive value of interventional animal models data.

Authors:  Caroline J Zeiss
Journal:  Drug Discov Today       Date:  2014-11-04       Impact factor: 7.851

Review 5.  Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.

Authors:  Carole Parsons; Wei Yin Lim; Clement Loy; Bernadette McGuinness; Peter Passmore; Stephanie A Ward; Carmel Hughes
Journal:  Cochrane Database Syst Rev       Date:  2021-02-03

Review 6.  Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis.

Authors:  Gaurav Pandey; Vibin Ramakrishnan
Journal:  Biophys Rev       Date:  2020-09-15

7.  Timosaponin B-II ameliorates scopolamine-induced cognition deficits by attenuating acetylcholinesterase activity and brain oxidative damage in mice.

Authors:  Xu Zhao; Chunmei Liu; Yu Qi; Lina Fang; Jie Luo; Kaishun Bi; Ying Jia
Journal:  Metab Brain Dis       Date:  2016-07-22       Impact factor: 3.584

Review 8.  Diagnosis and management of the patient with suspected dementia in primary care.

Authors:  Stefan Holzer; James P Warner; Steve Iliffe
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

9.  Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.

Authors:  Lars Sonde; Kristina Johnell
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

Review 10.  Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.

Authors:  Natalia Guzior; Anna Wieckowska; Dawid Panek; Barbara Malawska
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.